Neuronostics Secures £2.5m to Advance Neurological Diagnostics

Neuronostics Limited, a Bristol-based medical technology company specialising in digital biomarkers for neurological conditions, has successfully secured £2.5m in its latest funding round. The filing for this investment was made on 2026-04-24, with an allotment date of 2026-03-31. This capital injection is set to further propel the company's mission to revolutionise the diagnosis, treatment, and monitoring of neurological conditions globally.

Founded on 2017-12-22, Neuronostics addresses a critical need in healthcare by developing novel digital biomarkers through mathematical modelling. Their flagship product, BioEP, is designed to enhance epilepsy diagnosis by using background EEG data and mathematical modelling to predict the likelihood of seizures. This innovative approach aims to create faster paths to diagnosis and more effective treatment outcomes for patients. The company's web-based Neuronostics Platform delivers these solutions directly to clinicians in neurology centres, with a vision for digital biomarkers to become a routine part of neurological care worldwide, fostering a more proactive and anticipatory model of care.

According to its latest accounts, Neuronostics reported a revenue of £104.4k and a profit/loss of £-504,018. The company's latest accounts indicate 13 employees, while its LinkedIn profile suggests a team of 20. The company's specialties include epilepsy, medical diagnostics, healthcare technologies, computational neuroscience, mathematics, and software as a service.

This recent £2.5m funding round marks another significant step in Neuronostics' growth trajectory. While a specific valuation for this latest round has not been disclosed, the company has demonstrated consistent progress in attracting investment. Previous funding rounds include £162.6k on 2024-03-28 and £263.5k on 2024-03-08. Earlier rounds saw Neuronostics raise £500k on 2023-10-04 at a valuation of £5.2m, £849.4k on 2023-04-05 at a valuation of £4.7m, £228.9k on 2021-03-31 at a valuation of £2.2m, and £249k on 2021-03-30 at a valuation of £1.9m. In April 2024, Neuronostics also secured £2.1m in an oversubscribed seed funding round, which was led by the Ascension Life Fund, with additional backing from a syndicate of investors including QantX, the Cornwall and Isles of Scilly Investment Fund managed by The FSE Group, and Science Angel Syndicate. These previous investments highlight a sustained investor interest in Neuronostics' pioneering technology and its potential to transform neurological healthcare.

The funding landscape for UK HealthTech and MedTech companies is experiencing a period of strategic acceleration and structural evolution as the market transitions into 2026. After a period of market corrections and capital scarcity between 2023 and 2025, the outlook for 2026 suggests a sustained recovery in venture capital investment. In 2025, HealthTech companies in the United Kingdom raised £1.28bn ($1.61bn) in equity funding across 127 rounds, representing a 59.71% rise compared to 2024. The UK MedTech market alone is projected to reach £15.7bn in 2025, with a steady growth forecast to £20.5bn by 2030.

Investors are increasingly prioritising companies that demonstrate clear progress and clinical validation over purely speculative ideas. The market has shifted from a "growth-at-all-costs" paradigm to a disciplined focus on "profitable efficiency". This environment favours companies like Neuronostics, which are developing solutions with solid clinical evidence and a clear regulatory path. Emerging trends shaping MedTech investment in 2026 include the rise of precision medicine and AI, at-home diagnostics, and remote monitoring. Neuronostics' focus on digital biomarkers and a web-based platform aligns well with these trends, particularly the move towards remote monitoring and AI-driven diagnostics.

Government policy shifts and evolving NHS structures are also creating opportunities for HealthTech companies. Initiatives such as the £30m HealthTech Adoption Acceleration Fund and regulatory reforms aimed at simplifying processes are streamlining the path to market for innovative solutions. The UK's 10-Year Health Plan, published in July 2025, demonstrates a commitment to advancing innovation and attracting sustained investment across the life sciences sector, reflecting a shift towards digital systems and proactive prevention. This supportive ecosystem, coupled with a concentration of capital in fewer but larger transactions, positions companies with proven value propositions, such as Neuronostics, for continued growth and impact within the UK's dynamic health technology sector.